Veyonda® displays a range of anti-inflammatory properties. With inflammation being a key component of tumour growth, these anti-inflammatory actions of Veyonda®are believed to be making a significant contribution to its overall anti-cancer effect. More recently, the potential for Veyonda® as a treatment for septic shock has been discovered.
Some of these anti-inflammatory properties come as a result of the inhibitory effect of Veyonda® on sphingosine-1-phosphate (S1P) production, but others are via a potent inhibitory effect on the key pro-inflammatory signaling pathway, STING (stimulator of interferon genes).
An over-exuberant response of the STING pathway to tissue damage has been implicated in the cytokine release syndrome associated with septic shock, and associated with a high proportion of disability and death from the SARS-CoV-2 virus in COVID-19 patients.
In vitro data has confirmed the ability of Veyonda® to block the cytokine response to damage caused in human cell cultures by depressed oxygen levels, providing the rationale for conducting a study in COVID-19 patients.
Veyonda® is currently not approved in Australia or any other country